Comparison of Long-Acting Injectable and Oral Antipsychotics in Bipolar Disorder.

Eunice Kehui Deng Caige Huang V. Yan Kyung Jin Lee Shek-Ming Leung Vanessa W. S. Ng David J. Castle S. Chan F. T. T. Lai A. Nierenberg Yue Wei E. Chan

Sep 2026 · American Journal of Psychiatry · pp. appiajp20250793 · 0 citations

Medicine

TL;DR

LAIAs were associated with substantially less health care utilization and fewer relapses of manic and mixed episodes, and they were not associated with increased risk of nonpsychiatric hospitalizations, notably for cardiovascular disease.

DOI PubMed Semantic Scholar

View source

Similar papers

Review Open access Aug 2026

Long-Acting Injectable Antipsychotics in Schizophrenia and Comorbid Substance Use Disorder: A Systematic Review of the Literature

The present review suggests that LAIs may represent a valuable therapeutic strategy for patients with schizophrenia and comorbid SUD, although the available evidence remains heterogeneous in terms of study design, patient populations, and outcome measures.

Matteo Lupi, A. Carano, Eros Rossi et al. · Brain Science · 0 citations

Open access Sep 2026

Factors associated with rates of long-acting injectable antipsychotic use for schizophrenia: A subgroup analysis of the multinational ADVANCE study.

INTRODUCTION Long-acting injectable antipsychotics (LAIs) are underused despite known benefits. This subgroup analysis from the Attitudes DriVing regional differences in LAI ANtipsychotic utilization for schizophrenia among healthcare professionals (HCPs), patients, and CaregivErs (ADVANCE) study aimed to understand fa...

K. R. Franzenburg, Rolf T. Hansen, M. Suett et al. · Psychiatry Research · 0 citations

Sep 2026

Concurrent use of two long-acting injectable (LAI) antipsychotics in forensic patients with treatment-resistant schizophrenia: A case series.

ObjectiveDescribe concurrent use of two long-acting injectable (LAI) antipsychotics in selected patients with treatment-resistant schizophrenia and persistent aggression at a forensic health facility. Evidence remains limited for this off-licence strategy.MethodsRetrospective case series conducted at a specialist foren...

A. Rodrigo, Jacques Claassen, Daveena Mawren · Australasian Psychiatry · 0 citations

Open access Sep 2026

Differences in associations between long-acting injectable and oral antipsychotic prescribing and healthcare utilisation in people with intellectual disability: a self-controlled case series (LOID study)

Abstract Background Literature guiding the use of long-acting injectable antipsychotics (LAIAs) versus oral antipsychotics (OAs) in people with intellectual disability (PWID) remains scarce. Objective Examining the associations of LAIAs vs OAs with healthcare utilisation among PWID. Methods This self-controlled case se...

Shek-Ming Leung, Kyung Jin Lee, Yue Wei et al. · BMJ mental health · 0 citations

Open access Aug 2026

Effect of long-acting injectable antipsychotics on antipsychotic dose changes in patients with schizophrenia

A significant effect of initial dose, number of concomitant antipsychotics, and disorder duration before LAI initiation was found, and the importance of follow-up and dose reassessment after starting LAI treatment is underscored.

Tatsunori Suzuki, Keita Okinaga, Tomoe Abe et al. · Journal of Pharmaceutical He... · 0 citations

Sep 2026

Utilization of Long-Acting Injectable Antipsychotics and Clozapine in Coordinated Specialty Care: Data From EPINET.

Objective: We utilized the Early Psychosis Intervention Network (EPINET) platform to examine variability in utilization rates of 2 evidence-based pharmacologic treatments, long-acting injectable (LAI) formulations of antipsychotics and clozapine. Methods: Data come from 8 EPINET clinic consortia, called "hubs," compris...

John M. Kane, Nina R. Schooler, P. Marcy et al. · Journal of Clinical Psychiat... · 0 citations